Zumutor Biologics Inc., based in Boston and specializing in clinical-stage oncology, has commenced a Phase 1 clinical trial with ZM008. This trial will evaluate ZM008 both as a monotherapy

Flagship Pioneering and ProFound™ Therapeutics, both founded by Flagship, have announced a collaboration aimed at pioneering new treatments for obesity. This partnership represents the first initiative

Cyrus Biotechnology, Inc., based in Seattle, is spinning off its software and services division, Levitate Bio, to introduce the Cyrus platform to the broader biopharma sector. This move supports the development of its IdeS IgG degrading

Medable Inc., a leader in technology for modern clinical trials, has released important findings from a study conducted by the Partnership for Advancing Clinical Trials (PACT) consortium in partnership with the Tufts Center for the Study of Drug Development

Ipsen has announced that the U.S. Food and Drug Administration has granted accelerated approval for Iqirvo® 80 mg tablets. This medication is for treating primary biliary cholangitis and can be prescribed in combination

Can-Fite BioPharma Ltd., a company focused on developing proprietary small molecule drugs for cancer and inflammatory diseases, has announced that the Institutional Review Board (IRB) at Rabin Medical Center

Calico Life Sciences LLC, a biotechnology company co-founded by Alphabet and Arthur D. Levinson, Ph.D., has announced that their investigational drug fosigotifator has been accepted into the FDA's START Pilot Program.

BWXT Medical Ltd. has filed a Drug Master File with the U.S. Food and Drug Administration for its No Carrier Added Actinium-225 Active Pharmaceutical Ingredient. Ac-225, an alpha-emitting isotope, is pivotal in targeted alpha therapy, where it is combined

Qu Biologics Inc., a biopharmaceutical company focused on developing Site Specific Immunomodulators (SSIs) to enhance innate immune function, has partnered with Foundation Medicine, Inc

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, has advanced revumenib, its oral menin inhibitor, into the Phase 1b segment of its ongoing Phase 1/2 trial. This phase tests revumenib as a monotherapy for patients